Elanco Animal Health (NYSE:ELAN – Get Rating) and Hypera (OTCMKTS:HYPMY – Get Rating) are both mid-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, dividends, institutional ownership, analyst recommendations, profitability and earnings.
Institutional and Insider Ownership
0.1% of Hypera shares are owned by institutional investors. 0.6% of Elanco Animal Health shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Get Elanco Animal Health alerts:Analyst Recommendations
This is a breakdown of current recommendations and price targets for Elanco Animal Health and Hypera, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Elanco Animal Health | 1 | 6 | 0 | 0 | 1.86 |
| Hypera | 0 | 1 | 1 | 0 | 2.50 |
Elanco Animal Health currently has a consensus price target of $16.50, suggesting a potential upside of 74.42%. Given Elanco Animal Health's higher probable upside, research analysts plainly believe Elanco Animal Health is more favorable than Hypera.
Risk and Volatility
Elanco Animal Health has a beta of 0.92, meaning that its share price is 8% less volatile than the S&P 500. Comparatively, Hypera has a beta of 0.74, meaning that its share price is 26% less volatile than the S&P 500.
Profitability
This table compares Elanco Animal Health and Hypera's net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Elanco Animal Health | -1.74% | 7.57% | 3.50% |
| Hypera | N/A | N/A | N/A |
Valuation & Earnings
This table compares Elanco Animal Health and Hypera's gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Elanco Animal Health | $4.42 billion | 1.05 | -$78.00 million | ($0.15) | -63.06 |
| Hypera | $793.81 million | 5.76 | $251.25 million | N/A | N/A |
Hypera has lower revenue, but higher earnings than Elanco Animal Health.
About Elanco Animal Health
(Get Rating)
Elanco Animal Health, Inc. innovates, develops, manufactures, and markets products for pets and farm animals. It offers products through the following four categories: Companion Animal Disease Prevention, Companion Animal Therapeutics, Food Animal Future Protein & Health, and Food Animal Ruminants & Swine. The Companion Animal Disease Prevention category engages in the broadest parasiticide portfolios in the companion animal sector based on indications, species and formulations, with products that protect pets from worms, fleas and ticks. The Companion Animal Therapeutics category provides the details of a broad pain and osteoarthritis portfolio across species, modes of action, indications and disease stages. The Food Animal Future Protein & Health category includes vaccines, nutritional enzymes and animal-only antibiotics, serves the growing demand for protein and includes innovative products in poultry and aquaculture production, where demand for animal health products is outpacing overall industry growth. It also focuses on developing functional nutritional health products that promote food animal health, including enzymes, probiotics and prebiotics. The Food Animal Ruminants &
About Hypera
(Get Rating)
Hypera S.A. operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, MaxSulid, milgamma, Mioflex – A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands. The company also provides dermo-cosmetics products under the Mantecorp Skincare brands; and consumer health products under the Apracur, Benegrip, Coristina d, Engov, Epocler, Estomazil, and other brands. In addition, it offers nutritional and vitamin supplement products under the Tamarine, Vitasay, Biotônico Fontoura, and Zero-Cal brands; and similar and generic medicines under the Neo Química, Sodium Diclofenac, Hydroxyzine, Dipyron, Ibuprofen, Losartan Potassium, Mal Dexchlorpheniramine, Naproxene, Paracetamol, Simethicon, Loratadine, Omeprazole, Tadalaphyl, and Desogestrel brand names. The company was formerly known as Hypermarcas S.A. and changed its name to Hypera S.A. in February 2018. Hypera S.A. is based in São Paulo, Brazil.
Receive News & Ratings for Elanco Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elanco Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.